NCT03563014View on ClinicalTrials.gov

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

CompletedOBSERVATIONAL
Enrollment

164

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
DRUG

Radium-223 (Xofigo, Bay88-8223)

Follow the physician's prescription in routine clinical practice.

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY